Paul Tappenden BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0855
Fax: (+44) (0)114 222 0749
I am a Reader in Health Economic Modelling within the Health Economics and Decision Science Section at ScHARR. I have over 12 years’ experience in designing, developing and critically appraising health economic models across a number of disease areas. Since joining ScHARR in 2000, I have been involved in a number of research studies for the National Institute for Health and Care Excellence (NICE), including modelling the cost-effectiveness of beta-interferon and glatiramer-acetate in the management of multiple sclerosis, modelling the cost-effectiveness of influenza prophylaxis and modelling the cost-effectiveness of technologies for the prevention, detection, treatment and follow-up of colorectal cancer. I have also undertaken modelling assessments for the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. In 2011, I completed a fellowship funded by the NIHR evaluating the role and value of developing health economic models of whole disease and treatment pathways (Whole Disease Modelling).
My main research interests are:
• Health economic modelling
• Economic analyses of therapies for multiple sclerosis
• Economic analyses of cancer therapies
• Whole disease modelling
I currently teach on the MSc in Health Economics and Decision Science, the MSc in International Health Technology Assessment, Pricing and Reimbursement and the MSc(Res) in Translational Oncology.
I am Deputy Technical Director for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit. I am a member of NICE Technology Appraisal Committee C.
Amongst others, I am currently working on the following projects:
• The clinical effectiveness and cost-effectiveness of FeNO testing for the diagnosis and management of asthma (NICE)
• Frequency of follow-up for patients with intermediate grade adenomas (NIHR)
• The clinical effectiveness and cost-effectiveness of eculizumab for the treatment of atypical haemolytic uraemic syndrome (NICE)
• The clinical effectiveness and cost-effectiveness of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (NICE)
Paul Tappenden is based in Health Economics and Decision Science (HEDS).
- Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
- Tappenden P & Chilcott J (2014) Avoiding and Identifying Errors and Other Threats To the Credibility of Health Economic Models. Value in Health, 17(7), A585-A585.
- Tappenden P & Chilcott JB (2014) Avoiding and identifying errors and other threats to the credibility of health economic models.. Pharmacoeconomics, 32(10), 967-979.
- Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C & Brownlee K (2014) The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. PHARMACOECONOMICS, 32(2), 159-172.
- Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C & Cantrell A (2013) Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.. Health Technol Assess, 17(56), v-181.
- Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S , Mavranezouli I et al (2013) Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.. Health Technol Assess, 17(58), v-192.
- Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health.
- Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.. Value Health, 15(8), 1127-1136.
- Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.. Health Technol Assess, 14(25), iii-107.
- Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
- Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom.. Int J Technol Assess Health Care, 25(4), 470-478.
- Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.. Health Technol Assess, 13(11), iii-246.
- Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.. Value Health, 12(5), 657-665.
- Tappenden P, Jones R, Paisley S & Carroll C (2007) The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.. Eur J Cancer, 43(17), 2487-2494.
- Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) Option appraisal of population-based colorectal cancer screening programmes in England.. Gut, 56(5), 677-684.